Aethlon Medical (NASDAQ:AEMD – Get Free Report) had its target price reduced by stock analysts at HC Wainwright from $10.00 to $7.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock.
Separately, StockNews.com initiated coverage on Aethlon Medical in a report on Sunday. They issued a “sell” rating for the company.
Check Out Our Latest Report on Aethlon Medical
Aethlon Medical Stock Down 2.5 %
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
See Also
- Five stocks we like better than Aethlon Medical
- Market Cap Calculator: How to Calculate Market Cap
- Risk Tolerance vs Risk Capacity: Key Differences & How to Measure
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Ciena Stock: Powering the AI Boom – A Network Infrastructure Play
- How to Invest in Small Cap StocksĀ
- Is NVIDIA Stock Done Playing With the Market? Buy, Sell, or Hold
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.